Skip to main content

Payers' Guide

Stelara (Ustekinumab) Receives New FDA Indication for the Treatment of Patients with Active Psoriatic Arthritis

Tafinlar (Dabrafenib) and Mekinist (Trametinib): Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations

Lisa A. Raedler, PhD, RPh

Tecfidera (Dimethyl Fumarate), a New Oral Therapy Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis

Xiaflex (Collagenase Clostridium Histolyticum), First Drug Approved by the FDA for Peyronie’s Disease

Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Zaltrap: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen

Lynne Lederman, PhD, Medical Writer

Payers' Guide, FDA Approvals

Zytiga Receives an Expanded Indication for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy

Payers' Guide, FDA Approvals

Zioptan Receives FDA Approval for Patients with Open-Angle Glaucoma and/or Ocular Hypertension

Payers' Guide, FDA Approvals

Linzess: A Novel Treatment Option for Constipation Associated with Irritable Bowel Syndrome

Alice Goodman, Medical Writer

Payers' Guide, FDA Approvals

Perjeta: A New Option for Patients with HER2-Positive Metastatic Breast Cancer

Alice Goodman, Medical Writer

Page 17 of 19
Results 161 - 170 of 185